WFDC2 and ovarian cancer: They were able to identify an optimal biomarker panel comprised of four biomarkers (CA-125, HE4, CEA, and VCAM-1) that discriminated early stage ovarian cancer from healthy controls, with a specificity of 98% and a sensitivity of 86%.